Covid-19 roundup: FDA ad­dress­es risk of ex­ces­sive bleed­ing af­ter J&J vac­cine; No­vavax vac­cine gets OK in South Ko­rea 

The FDA has added a new risk to the fact sheet for J&J’s Covid-19 vac­cine: im­mune throm­bo­cy­tope­nia, a con­di­tion that can lead to easy or ex­ces­sive bruis­ing and bleed­ing.

Reg­u­la­tors is­sued a let­ter to J&J on Tues­day alert­ing it of the change.

“Re­ports of ad­verse events fol­low­ing use of the Janssen COVID-19 Vac­cine un­der emer­gency use au­tho­riza­tion sug­gest an in­creased risk of im­mune throm­bo­cy­tope­nia (ITP) dur­ing the 42 days fol­low­ing vac­ci­na­tion,” the let­ter states.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER